Search

Your search keyword '"Huang, Yi-Hsiang"' showing total 1,738 results
Start Over Author "Huang, Yi-Hsiang"
1,738 results on '"Huang, Yi-Hsiang"'

51. Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation.

Author

Wu, Kuo‐Cheng, Lee, I‐Cheng, Chi, Chen‐Ta, Liu, Chien‐An, Chiu, Nai‐Chi, Hsu, Shao‐Jung, Lee, Pei‐Chang, Wu, Chi‐Jung, Luo, Jiing‐Chyuan, Hou, Ming‐Chih, and Huang, Yi‐Hsiang

Subjects
CATHETER ablation, OVERALL survival, HEPATOCELLULAR carcinoma, DISEASE relapse, TREATMENT effectiveness
Abstract

Summary: Background: The benefits of HCV eradication on distinct recurrence patterns and long‐term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long‐term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR). Methods: We retrospectively enrolled 274 patients receiving RFA for HCV‐related HCC, including 73 and 88 patients treated with interferon‐based (IFN) and direct‐acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation. Results: SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB‐4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB‐4 score after SVR, rather than the baseline FIB‐4, predicted distant recurrence. Conclusions: HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV‐related HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

52. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression.

Author

Liu, Tsung-Hao, Chen, San-Chi, Rau, Kun-Ming, Lu, Li-Chun, Lin, Po-Ting, Su, Yung-Yeh, Teng, Wei, Lai, Shiue-Wei, Yeh, Ren-Hua, Kao, Tsui-Mai, Lee, Pei-Chang, Wu, Chi-Jung, Chen, Chien-Hung, Hsu, Chih-Hung, Lin, Shi-Ming, Huang, Yi-Hsiang, Chen, Li-Tzong, Cheng, Ann-Lii, and Shen, Ying-Chun

Subjects
IMMUNE checkpoint inhibitors, CHRONIC active hepatitis, VIRAL hepatitis, OVERALL survival, HEPATOCELLULAR carcinoma
Abstract

Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively. Results: A total of 91 durable responders (63 PR and 28 SD) were identified. The majority had chronic viral hepatitis (n = 69, 75.8%). Forty-seven (51.6%) and 44 (48.4%) patients received the index immunotherapy as first-line and second- or beyond-line therapy, respectively. Fifty-four (59.3%) patients subsequently developed progression, with a predominant pattern of oligoprogression (66.7%). The median overall survival (OS) was 46.2 months (95% CI: 34.1–58.3). For patients with subsequent progression, employment of locoregional therapy (LRT) for progression was associated with prolonged OS (univariate analysis: hazard ratio [HR] 0.397, p = 0.009; multivariate analysis: HR 0.363, p = 0.050). Patients with oligoprogression who received LRT showed longer median OS than those who did not (48.4 vs. 20.5 months, p < 0.001). In contrast, the median OS of patients with polyprogression who received LRT was not different from those without LRT (27.7 vs. 25.5 months, p = 0.794). Conclusion: Approximately 60% of the post-immunotherapy durable responders of HCC subsequently develop progression. Proactive LRT may further rescue patients who develop subsequent oligoprogression. Prospective studies are mandatory to clarify the proper management of durable responders with subsequent progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

53. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D'Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, and Phen, Samuel

Published
2024
Full Text
View/download PDF

54. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Author

Cheng, Pin-Nan, Mo, Lein-Ray, Chen, Chun-Ting, Chen, Chi-Yi, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Tseng, Kuo-Chih, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Chou, Kwok-Hsiung, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Cheng, Chien-Yu, Tsai, Ming-Chang, Liu, Chun-Jen, Dai, Chia-Yen, Lin, Han-Chieh, Kao, Jia-Horng, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

59. The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan

Author

Chang, Chin-Wei, primary, Hsu, Wei-Fan, additional, Tseng, Kuo-Chih, additional, Chen, Chi-Yi, additional, Cheng, Pin-Nan, additional, Hung, Chao-Hung, additional, Lo, Ching-Chu, additional, Bair, Ming-Jong, additional, Chen, Chien-Hung, additional, Lee, Pei-Lun, additional, Lin, Chun-Yen, additional, Kuo, Hsing-Tao, additional, Chen, Chun-Ting, additional, Yang, Chi-Chieh, additional, Huang, Jee-Fu, additional, Tai, Chi-Ming, additional, Hu, Jui-Ting, additional, Lin, Chih-Lang, additional, Su, Wei-Wen, additional, Tsai, Wei-Lun, additional, Huang, Yi-Hsiang, additional, Cheng, Chien-Yu, additional, Lin, Chih-Lin, additional, Wang, Chia-Chi, additional, Yang, Sheng-Shun, additional, Mo, Lein-Ray, additional, Chen, Guei-Ying, additional, Chang, Chun-Chao, additional, Wang, Szu-Jen, additional, Huang, Chia-Sheng, additional, Hsieh, Tsai-Yuan, additional, Lin, Chih-Wen, additional, Lee, Tzong-Hsi, additional, Chong, Lee-Won, additional, Huang, Chien-Wei, additional, Chang, Shiuh-Nan, additional, Tsai, Ming-Chang, additional, Hsu, Shih-Jer, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Lin, Han-Chieh, additional, Tsai, Pei-Chien, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Yu, Ming-Lung, additional, and Peng, Cheng-Yuan, additional

Published
2024
Full Text
View/download PDF

62. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Yeh, Ming-Lun, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Chen, Chi-Yi, Kuo, Hsing-Tao, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi‐Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Tsai, Pei-Chien, Peng, Cheng-Yuan, Liu, Chun-Jen, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

66. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Author

Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., and Zhu, Andrew X.

Published
2021
Full Text
View/download PDF

69. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Author

Pfister, Dominik, Núñez, Nicolás Gonzalo, Pinyol, Roser, Govaere, Olivier, Pinter, Matthias, Szydlowska, Marta, Gupta, Revant, Qiu, Mengjie, Deczkowska, Aleksandra, Weiner, Assaf, Müller, Florian, Sinha, Ankit, Friebel, Ekaterina, Engleitner, Thomas, Lenggenhager, Daniela, Moncsek, Anja, Heide, Danijela, Stirm, Kristin, Kosla, Jan, Kotsiliti, Eleni, Leone, Valentina, Dudek, Michael, Yousuf, Suhail, Inverso, Donato, Singh, Indrabahadur, Teijeiro, Ana, Castet, Florian, Montironi, Carla, Haber, Philipp K., Tiniakos, Dina, Bedossa, Pierre, Cockell, Simon, Younes, Ramy, Vacca, Michele, Marra, Fabio, Schattenberg, Jörn M., Allison, Michael, Bugianesi, Elisabetta, Ratziu, Vlad, Pressiani, Tiziana, D’Alessio, Antonio, Personeni, Nicola, Rimassa, Lorenza, Daly, Ann K., Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Vogel, Arndt, Peck-Radosavljevic, Markus, Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Trojan, Jörg, Schulze, Kornelius, Wege, Henning, Koch, Sandra, Weinmann, Arndt, Bueter, Marco, Rössler, Fabian, Siebenhüner, Alexander, De Dosso, Sara, Mallm, Jan-Philipp, Umansky, Viktor, Jugold, Manfred, Luedde, Tom, Schietinger, Andrea, Schirmacher, Peter, Emu, Brinda, Augustin, Hellmut G., Billeter, Adrian, Müller-Stich, Beat, Kikuchi, Hiroto, Duda, Dan G., Kütting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias Philip, Rahbari, Nuh, Mei, Henrik E., Schulz, Axel Ronald, Ringelhan, Marc, Malek, Nisar, Spahn, Stephan, Bitzer, Michael, Ruiz de Galarreta, Marina, Lujambio, Amaia, Dufour, Jean-Francois, Marron, Thomas U., Kaseb, Ahmed, Kudo, Masatoshi, Huang, Yi-Hsiang, Djouder, Nabil, Wolter, Katharina, Zender, Lars, Marche, Parice N., Decaens, Thomas, Pinato, David J., Rad, Roland, Mertens, Joachim C., Weber, Achim, Unger, Kristian, Meissner, Felix, Roth, Susanne, Jilkova, Zuzana Macek, Claassen, Manfred, Anstee, Quentin M., Amit, Ido, Knolle, Percy, Becher, Burkhard, Llovet, Josep M., and Heikenwalder, Mathias

Published
2021
Full Text
View/download PDF

71. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients

Author

Choi, Won-Mook, primary, Yip, Terry Cheuk-Fung, additional, Kim, W. Ray, additional, Yee, Leland J., additional, Brooks-Rooney, Craig, additional, Curteis, Tristan, additional, Clark, Laura J., additional, Jafry, Zarena, additional, Chen, Chien-Hung, additional, Chen, Chi-Yi, additional, Huang, Yi-Hsiang, additional, Jin, Young-Joo, additional, Jun, Dae Won, additional, Kim, Jin-Wook, additional, Park, Neung Hwa, additional, Peng, Cheng-Yuan, additional, Shin, Hyun Phil, additional, Shin, Jung Woo, additional, Yang, Yao-Hsu, additional, Wong, Grace Lai-Hung, additional, and Lim, Young-Suk, additional

Published
2024
Full Text
View/download PDF

72. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients

Author

Luan, Chih-Hsuan, primary, Su, Pin-Shuo, additional, Chu, Chi-Jen, additional, Lin, Chung-Chi, additional, Su, Chien-Wei, additional, Luo, Jiing-Chyuan, additional, Lee, I-Cheng, additional, Chi, Chen-Ta, additional, Lee, Shou-Dong, additional, Wang, Yuan-Jen, additional, Lee, Fa-Yauh, additional, Huang, Yi-Hsiang, additional, and Hou, Ming-Chih, additional

Published
2024
Full Text
View/download PDF

75. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

77. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Maria Fulgenzi, Claudia Angela, additional, D’Alessio, Antonio, additional, Pomej, Katharina, additional, Roig, Marta Bofill, additional, Meyer, Elias Laurin, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Wu, Linda, additional, Ang, Celina, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Stefanini, Bernardo, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Wietharn, Brooke, additional, Parisi, Alessandro, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Silletta, Marianna, additional, Trauner, Michael, additional, Samson, Adel, additional, Wege, Henning, additional, Piscaglia, Fabio, additional, Galle, Peter R., additional, Stauber, Rudolf, additional, Kudo, Masatoshi, additional, Singal, Amit G., additional, Itani, Aleena, additional, Ulahannan, Susanna V., additional, Parikh, Neehar D., additional, Cortellini, Alessio, additional, Kaseb, Ahmed, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Pinter, Matthias, additional

Published
2023
Full Text
View/download PDF

78. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

85. Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients

Author

Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Gau, Jyh-Pyng, Yang, Ching-Fen, Yu, Yuan-Bin, Liu, Chun-Yu, Liu, Jin-Hwang, Chen, Po-Min, Tzeng, Cheng-Hwai, Chan, Yu-Jiun, Yang, Muh-Hwa, and Huang, Yi-Hsiang

Subjects
Cancer, Lymphoma, Stem Cell Research, Liver Disease, Hepatitis, Chronic Liver Disease and Cirrhosis, Infectious Diseases, Hepatitis - B, Rare Diseases, Clinical Research, Hematology, Digestive Diseases, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Female, Hepatitis B Surface Antigens, Hepatitis B virus, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Retrospective Studies, Rituximab, Taiwan, Clinical Sciences, Arthritis & Rheumatology
Abstract

Rituximab causes hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-seronegative patients with CD20-positive B-cell non-Hodgkin lymphoma (CD20 NHL), especially for those seropositive to the antibody of core antigen (anti-HBc). Clinical hepatitis usually develops after reverse seroconversion of HBsAg (HBV-RS), indicated by the reappearance of HBsAg in serum. Because of the relatively high prevalence of anti-HBc seropositivity in unvaccinated HBsAg-seronegative adults in an HBV hyperendemic area, we aimed to investigate additional factors influencing the development of rituximab-associated HBV-RS.Between January 2000 and December 2010, unvaccinated HBsAg-seronegative adults with CD20 NHL who had received rituximab-containing therapy but not anti-HBV agents were enrolled. Patients with and without HBV-RS were compared in terms of clinical factors and treatments including the number of cycles of rituximab therapy, and transplantation. Competing risk regression was used to identify the factors associated with HBV-RS.For the 482 patients enrolled, the serological status of anti-HBc was available in 75.9%, with a seropositivity rate of 86.6%. At the last follow-up, a total of 33 (6.85%) patients had HBV-RS, with 95.8% anti-HBc seropositive, 78.9% anti-HBs seropositive, and none anti-HCV seropositive. HBV-RS patients have received more cycles (≥6) and prolonged durations of rituximab therapy, and hematopoietic stem cell transplantation. The overall survival was not different between patients with and those without HBV-RS. At the time of HBV-RS, a total of 25 (78.1%) patients had hepatitis flare, especially when HBV-RS appeared during/after induction therapy (100%, 10 of 10). Three (9.1%) patients had fulminant hepatitis, resulting in death in 1 (3%) patient. A higher rituximab cycle intensity was associated with a higher rate of hepatitis flare at the time of HBV-RS. When death in the absence of HBV-RS was considered as the competing risk, the univariate and multivariate regression analyses showed that several factors were independently associated with the development of HBV-RS, including anti-HCV seronegativity, histological subtype of posttransplant lymphoproliferative disorders, ≥6 cycles of rituximab therapy, and succeeding hematopoietic stem cell transplantation.The findings of our study identify additional factors influencing the development of rituximab-associated HBV-RS in HBsAg-seronegative adults with CD20 NHL.

Published
2015

90. Empowering Portable Optoelectronics With Computer Vision for Intraoral Cavity Detection

Author

Khuntia, Sucharita, Fan, Sue-Yuan, Juan, Po-Hsiang, Liou, Ci-Ruei, Huang, Yi-Hsiang, Singh, Kanishk, Ogwo, Chukwuebuka, and Tai, Li-Chia

Abstract

Tooth decay is a chronic disease resulting in pain, infection, and tooth loss. This illness is common because many factors, such as poor oral hygiene, sugar consumption, and microbial flora, contribute to dental cavities. Untreated or undetected tooth decay often escalates to a more severe stage, emphasizing the importance of early detection and intervention. We propose a portable, low-cost, and ergonomic optoelectronic device to provide a possible solution for the early detection of dental cavities before annual or regular dental checkups for the first time. This device integrates mini cameras on top of a dental impression tray to capture images of the teeth, and the photographs can be transmitted via Wi-Fi to the cloud for real-time cavity detection through a you only look once (YOLO) algorithm that is based on a convolutional neural network (CNN). Our results show the precision, recall, and mean average precision (mAP)@0.5:0.95 for YOLOv5 (0.72, 0.70, 0.75), YOLOv6 (0.59, 0.50, 0.58), and YOLOv7 (0.93, 0.94, 0.82). We also compared the YOLO algorithm with traditional techniques such as support vector machine (SVM) and k-nearest neighbor (kNN) algorithms. This intraoral cavity detection system paves the way for early detection of dental cavities with quick accessibility and affordable cost. We foresee that this optoelectronic device will play a role in advancing biomedical technologies, ultimately promoting the long-term well-being of individuals.

Published
2024
Full Text
View/download PDF

93. Ser38‐His93‐Asn91 triad confers resistance of JFH1 HCV NS5A‐Y93H variant to NS5A inhibitors.

Author

Lee, Wei‐Ping, Tsai, Keng‐Chang, Liao, Shi‐Xian, Huang, Yi‐Hsiang, Hou, Ming‐Chih, and Lan, Keng‐Hsin

Subjects
ANTIVIRAL agents, DIMERS, DIMERIZATION, DATABASES, HEPATITIS C virus, VIRAL nonstructural proteins
Abstract

HCV NS5A is a dimeric phosphoprotein involved in HCV replication. NS5A inhibitors are among direct‐acting antivirals (DAA) for HCV therapy. The Y93H mutant of NS5A is resistant to NS5A inhibitors, but the precise mechanism remains unclear. In this report, we proposed a Ser38‐His93‐Asn91 triad to dissect the mechanism. Using pymol 1.3 software, the homology structure of JFH1 NS5A was determined based on the dimer structure of genotype 1b extracted from the database Protein DataBank (www.ebi.ac.uk/pdbsum) with codes 1ZH1 and 3FQM/3FQQ. FLAG‐NS5A‐WT failed to form dimer in the absence of nonstructural proteins from subgenomic replicon (NS3‐5A); however, FLAG‐NS5A‐Y93H was able to form dimer without the aid of NS3‐5A. The Ser38‐His93‐Asn91 triad in the dimer of the Y93H variant predicts a structural crash of the cleft receiving the NS5A inhibitor daclatasvir. The dimerization assay revealed that the existence of JFH1‐NS5A‐1ZH1 and ‐3FQM homology dimers depended on each other for existence and that both NS5A‐WT 1ZH1 and 3FQM dimers cooperated to facilitate RNA replication. However, NS5A‐Y93H 1ZH1 alone could form dimer and conduct RNA replication in the absence of the 3FQM structure. In conclusion, this study provides novel insight into the functional significance of the Ser38‐His93‐Asn91 triad in resistance of the Y93H variant to NS5A inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

96. Artificial intelligence predicts direct-acting antivirals failure among HCV patients: A Nationwide HCV Registry Program

Author

Lu, Ming-Ying, primary, Huang, Chung-Feng, additional, Hung, Chao-Hung, additional, Tai, Chi‐Ming, additional, Mo, Lein-Ray, additional, Kuo, Hsing-Tao, additional, Tseng, Kuo-Chih, additional, Lo, Ching-Chu, additional, Bair, Ming-Jong, additional, Wang, Szu-Jen, additional, Huang, Jee-Fu, additional, Yeh, Ming-Lun, additional, Chen, Chun-Ting, additional, Tsai, Ming-Chang, additional, Huang, Chien-Wei, additional, Lee, Pei-Lun, additional, Yang, Tzeng-Hue, additional, Huang, Yi-Hsiang, additional, Chong, Lee-Won, additional, Chen, Chien-Lin, additional, Yang, Chi-Chieh, additional, Yang, Sheng‐Shun, additional, Cheng, Pin-Nan, additional, Hsieh, Tsai-Yuan, additional, Hu, Jui-Ting, additional, Wu, Wen-Chih, additional, Cheng, Chien-Yu, additional, Chen, Guei-Ying, additional, Zhou, Guo-Xiong, additional, Tsai, Wei-Lun, additional, Kao, Chien-Neng, additional, Lin, Chih-Lang, additional, Wang, Chia-Chi, additional, Lin, Ta-Ya, additional, Lin, Chih‐Lin, additional, Su, Wei-Wen, additional, Lee, Tzong-Hsi, additional, Chang, Te-Sheng, additional, Liu, Chun-Jen, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Peng, Cheng-Yuan, additional, Tsai, Chun-Wei-, additional, Chen, Chi-Yi, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

97. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Author

Dharmapuri, Sirish, primary, Özbek, Umut, additional, Jethra, Hiren, additional, Jun, Tomi, additional, Marron, Thomas U, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Muzaffar, Mahvish, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Fulgenzi, Claudia, additional, Amara, Suneetha, additional, Weinmann, Arndt, additional, Personeni, Nicola, additional, Scheiner, Bernhard, additional, Pressiani, Tiziana, additional, Navaid, Musharraf, additional, Bengsch, Bertram, additional, Paul, Sonal, additional, Khan, Uqba, additional, Bettinger, Dominik, additional, Nishida, Naoshi, additional, Mohamed, Yehia Ibrahim, additional, Vogel, Arndt, additional, Gampa, Anuhya, additional, Korolewicz, James, additional, Cammarota, Antonella, additional, Kaseb, Ahmed, additional, Galle, Peter R, additional, Pillai, Anjana, additional, Wang, Ying-Hong, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, D’Alessio, Antonio, additional, Rimassa, Lorenza, additional, Pinato, David James, additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

98. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Qin, Shukui, primary, Chen, Minshan, additional, Cheng, Ann-Lii, additional, Kaseb, Ahmed O, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam C, additional, Zhou, Jian, additional, Wang, Lu, additional, Wen, Xiaoyu, additional, Heo, Jeong, additional, Tak, Won Young, additional, Nakamura, Shinichiro, additional, Numata, Kazushi, additional, Uguen, Thomas, additional, Hsiehchen, David, additional, Cha, Edward, additional, Hack, Stephen P, additional, Lian, Qinshu, additional, Ma, Ning, additional, Spahn, Jessica H, additional, Wang, Yulei, additional, Wu, Chun, additional, Chow, Pierce K H, additional, Thompson, Alexander, additional, Danta, Mark, additional, Poursoltan, Pirooz, additional, Kiberu, Andrew, additional, Chittajallu, Renuka, additional, Sood, Siddarth, additional, Stauber, Rudolf, additional, Pinter, Matthias, additional, Peck-Radosavljevic, Markus, additional, Decaestecker, Jochen, additional, Cuyle, Pieter-Jan, additional, Verset, Gontran, additional, Van Vlierberghe, Hans, additional, De Azevedo, Sergio, additional, Andrade, Livia, additional, Cunha Júnior, Ademar, additional, Faria, Luiza, additional, Yen, Cheng Tzu, additional, Colli, Leandro, additional, Asselah, Jamil, additional, Kavan, Petr, additional, Marquez, Vladimir, additional, Brahmania, Mayur, additional, Li, Qiang, additional, Xing, Baocai, additional, Guo, Yabing, additional, Chen, Zhendong, additional, Zhao, Haitao, additional, Peng, Tao, additional, Wang, Liming, additional, Liu, Hongming, additional, Wu, Feixiang, additional, Qin, Lunxiu, additional, Zheng, Qichang, additional, Ying, Jieer, additional, Li, Haitao, additional, Wen, Tianfu, additional, Qin, Shukui, additional, Liu, Yunpeng, additional, Wang, Boqing, additional, Bai, Yuxian, additional, He, Yifu, additional, Zhao, Hong, additional, Zhou, Dong, additional, Dai, Chaoliu, additional, Teng, Gaojun, additional, Cui, Shuzhong, additional, Gao, Yi, additional, Zhang, Xizhi, additional, Lu, Zheng, additional, Yin, Tao, additional, Ding, Youming, additional, Jia, Weidong, additional, Xia, Yongxiang, additional, Sun, Beicheng, additional, Xia, Qiang, additional, Yuan, Yufeng, additional, Sun, Huichuan, additional, Shi, Xuetao, additional, Guzmán, Adrián, additional, Corrales, Luis, additional, Kral, Zdenek, additional, Priester, Peter, additional, Kubala, Eugen, additional, Blanc, Jean Frederic, additional, Bourliere, Marc, additional, Peron, Jean Marie, additional, Borg, Christophe, additional, Bronowicki, Jean-Pierre, additional, Ganne, Nathalie, additional, Decaens, Thomas, additional, Heurgue, Alexandra, additional, Trojan, Joerg, additional, Gonzalez-Carmona, Maria Angeles, additional, Roderburg, Christoph, additional, Ettrich, Thomas, additional, Schotten, Clemens, additional, Kandulski, Arne, additional, Yau, Thomas, additional, Chan, Lam, additional, Scartozzi, Mario, additional, Masi, Gianluca, additional, Fanello, Silvia, additional, Battezzati, Pier Maria, additional, Leonardi, Francesco, additional, Ghidini, Michele, additional, Morimoto, Manabu, additional, Hidaka, Hisashi, additional, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Kato, Naoya, additional, Hagihara, Atsushi, additional, Koga, Hironori, additional, Arakawa, Tomohiro, additional, Nakamura, Ikuo, additional, Kawamura, Yusuke, additional, Kawaoka, Tomokazu, additional, Shimada, Mitsuo, additional, Hasegawa, Kiyoshi, additional, Marusawa, Hiroyuki, additional, Nakamura, Shinchiro, additional, Hiraoka, Atsushi, additional, Hayashi, Hiromitsu, additional, Takeda, Shin, additional, Paik, Seung Woon, additional, Kim, Do Young, additional, Lee, Jung Il, additional, Jeong, Sook-Hyang, additional, Kim, Won, additional, Kim, Hyeyeong, additional, Chon, Hong Jae, additional, Cheong, Jaeyoun, additional, Yoon, Seung Kew, additional, Yoon, Jung-Hwan, additional, Villalobos, Ricardo, additional, Martinez Rodriguez, Jorge Luis, additional, Oyervides Juarez, Victor, additional, Hernández, Carlos Alberto, additional, Klumpen, Heinz-Josef, additional, de Vos-Geelen, Judith, additional, Gane, Edward, additional, Montenegro, Paola, additional, Torres Mattos, Cesar, additional, Janczewska, Ewa, additional, Kawecki, Maciej, additional, Nowakowska-Zajdel, Ewa, additional, Fedenko, Alexander, additional, Granov, Dmitrii, additional, Alyasova, Anna, additional, Sekacheva, Marina, additional, Ledin, Evgeny, additional, Samol, Jens, additional, Toh, Han Chong, additional, Calvo Campos, Mariona, additional, Gomez Martin, Carlos, additional, Lopez Lopez, Carlos, additional, Muñoz Martin, Andres Jesus, additional, Calleja Panero, Jose Luis, additional, Montero Alvarez, Jose Luis, additional, Reig Monzón, Maria, additional, Delgado Mingorance, Ignacio, additional, Minguez Rosique, Beatriz, additional, Cheng, Ann Lii, additional, Huang, Yi-Hsiang, additional, Lin, Shi-Ming, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Su, Wei-Wen, additional, Korphaisarn, Krittiya, additional, Maneenil, Kunlatida, additional, Samdaengpan, Chayanee, additional, Tharavichitkul, Ekkapong, additional, Ozguroglu, Mustafa, additional, Kose, Fatih, additional, Harputluoglu, Hakan, additional, Buchschacher, Gary, additional, Thuluvath, Paul, additional, Xiong, Henry, additional, Patel, Mital, additional, Gold, Philip, additional, Li, Daneng, additional, Brooks, Gabriel, additional, Masood, Ashiq, additional, Patel, Reema, additional, George, Ben, additional, Salgia, Reena, additional, Manji, Gulam, additional, Crow, Mary, additional, Kaseb, Ahmed, additional, Dugan, Matthew, additional, Kadakia, Kunal, additional, Kardosh, Adel, additional, Gibbs, John, additional, Shah, Ashesh, additional, and Burris III, Howard, additional

Published
2023
Full Text
View/download PDF

100. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Author

Joerg, Vincent, primary, Scheiner, Bernhard, additional, D´Alessio, Antonio, additional, Fulgenzi, Claudia A.M., additional, Schönlein, Martin, additional, Kocheise, Lorenz, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Kaseb, Ahmed, additional, Wang, Yinghong, additional, Mathew, Antony, additional, Kuang, Andrew, additional, Muzaffar, Mahvish, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Phen, Samuel, additional, Cheon, Jaekyung, additional, Lee, Pei-Chang, additional, Balcar, Lorenz, additional, Krall, Anja, additional, Ang, Celina, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Bengsch, Bertram, additional, Rimassa, Lorenza, additional, Weinmann, Arndt, additional, Stauber, Rudolf, additional, Korolewicz, James, additional, Pinter, Matthias, additional, Singal, Amit G., additional, Chon, Hong Jae, additional, Pinato, David J., additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results